MedPage Today) — NEW YORK CITY — A gene therapy for age-related macular degeneration (AMD) led to extended treatment-free intervals and durable improvement in visual acuity and retinal thickening, a preliminary trial showed.
ADVM-022 (ixoberogene…
Read More
